Oculis (OCS) H.C. Wainwright 26th Annual Global Investment Conference summary

Conference overview

• Over 600 companies presented across life sciences, cryptocurrency, fintech, technology, media, clean tech, metals, mining, and growth sectors.

• H.C. Wainwright provides corporate finance and strategic advisory services, with 24 senior analysts and coverage of 636 companies.

• Attendees were invited to participate in one-on-one meetings, corporate presentations, and panels, available both live and via streaming.

Company highlights and achievements

• Achieved Nasdaq listing in 2023 and a positive phase III stage one result for a topical eye drop in DME, a first for retinal indications.

• Continued phase III DIAMOND I and II trials in DME and positive RELIEF trial results in dry eye disease with Licaminlimab in 2024.

• Listed on Nasdaq Iceland to meet investor demand, reflecting the company's Icelandic origins.

• Raised over $300 million, with financing secured through 2026.

Clinical pipeline and trial updates

• OCS-01 in phase III for DME and ocular surgery, with full enrollment in DIAMOND I and II as the next catalyst; FDA NDA readiness for ocular surgery expected in Q1 2025.

• OCS-02 (Licaminlimab) showed positive phase II results in dry eye; FDA consultation for next trial design planned for Q1 2025.

• OCS-05, a neuroprotective SGK2 activator, is in the ACUITY trial for acute optic neuritis, with a readout expected in Q4.